Effects of sulfate deprivation on the production of chondroitin/dermatan sulfate by cultures of skin fibroblasts from normal and diabetic individuals.
Human skin fibroblast monolayer cultures from two normal men, three Type I diabetic men, and one Type I diabetic woman were incubated with [3H]glucosamine in the presence of diminished concentrations of sulfate. Although total synthesis of [3H]chondroitin/dermatan glycosaminoglycans varied somewhat between cell lines, glycosaminoglycan production was not affected within any line when sulfate levels were decreased from 0.3 mM to 0.06 mM to 0.01 mM to 0 added sulfate. Lowering of sulfate concentrations resulted in diminished sulfation of chondroitin/dermatan in a progressive manner, so that overall sulfation dropped to as low as 19% for one of the lines. Sulfation of chondroitin to form chondroitin 4-sulfate and chondroitin 6-sulfate was progressively and equally affected by decreasing the sulfate concentration in the culture medium. However, sulfation to form dermatan sulfate was preserved to a greater degree, so that the relative proportion of dermatan sulfate to chondroitin sulfate increased. Essentially all the nonsulfated residues were susceptible to chondroitin AC lyase, indicating that little epimerization of glucuronic acid residues to iduronic acid had occurred in the absence of sulfation. These results confirm the previously described dependency of glucuronic/iduronic epimerization on sulfation, and indicate that sulfation of the iduronic acid-containing disaccharide residues of dermatan can take place with sulfate concentrations lower than those needed for 6-sulfation and 4-sulfation of the glucuronic acid-containing disaccharide residues of chondroitin. There were considerable differences among the six fibroblast lines in susceptibility to low sulfate medium and in the proportion of chondroitin 6-sulfate, chondroitin 4-sulfate, and dermatan sulfate. However, there was no pattern of differences between normals and diabetics.
Silbert
C K
CK
Connective Tissue Research Laboratory, Veterans Administration Outpatient Clinic, Boston, Massachusetts.
Humphries
D E
DE
Palmer
M E
ME
Silbert
J E
JE
D053674:Aggrecans; D002478:Cells, Cultured; D002808:Chondroitin Lyases / Q000494:pharmacology; D011508:Chondroitin Sulfate Proteoglycans / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000378:metabolism*; D016326:Extracellular Matrix Proteins; D005260:Female; D005347:Fibroblasts / Q000187:drug effects / Q000378:metabolism*; D005965:Glucuronates / Q000378:metabolism; D020723:Glucuronic Acid; D006023:Glycoproteins / Q000378:metabolism*; D006801:Humans; D007067:Iduronic Acid / Q000378:metabolism; D037181:Lectins, C-Type; D008297:Male; D011509:Proteoglycans; D014316:Tritium
D053674:Aggrecans; D011508:Chondroitin Sulfate Proteoglycans; D016326:Extracellular Matrix Proteins; D005965:Glucuronates; D006023:Glycoproteins; D037181:Lectins, C-Type; D011509:Proteoglycans; D014316:Tritium; D007067:Iduronic Acid; D020723:Glucuronic Acid; D002808:Chondroitin Lyases